company background image
BLUE

bluebird bio NasdaqGS:BLUE Stock Report

Last Price

US$7.65

Market Cap

US$634.3m

7D

7.3%

1Y

-24.3%

Updated

29 Nov, 2022

Data

Company Financials +
BLUE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

BLUE Stock Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.

bluebird bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share PriceUS$7.65
52 Week HighUS$11.70
52 Week LowUS$2.87
Beta0.98
1 Month Change22.60%
3 Month Change30.99%
1 Year Change-24.33%
3 Year Change-90.99%
5 Year Change-95.30%
Change since IPO-71.57%

Recent News & Updates

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Recent updates

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Nov 08
bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Newsflash: bluebird bio, Inc. (NASDAQ:BLUE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 11
Newsflash: bluebird bio, Inc. (NASDAQ:BLUE) Analysts Have Been Trimming Their Revenue Forecasts

What You Need To Know About The bluebird bio, Inc. (NASDAQ:BLUE) Analyst Downgrade Today

Jul 22
What You Need To Know About The bluebird bio, Inc. (NASDAQ:BLUE) Analyst Downgrade Today

We Think bluebird bio (NASDAQ:BLUE) Can Afford To Drive Business Growth

Jul 21
We Think bluebird bio (NASDAQ:BLUE) Can Afford To Drive Business Growth

Industry Analysts Just Upgraded Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Forecasts By 2.7%

Apr 21
Industry Analysts Just Upgraded Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Forecasts By 2.7%

Analysts Have Just Cut Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Estimates By 15%

Feb 17
Analysts Have Just Cut Their bluebird bio, Inc. (NASDAQ:BLUE) Revenue Estimates By 15%

Shareholder Returns

BLUEUS BiotechsUS Market
7D7.3%0.2%0.3%
1Y-24.3%-16.1%-20.5%

Return vs Industry: BLUE underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: BLUE underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement14.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: BLUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BLUE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1992518Andrew Obenshainhttps://www.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLUE fundamental statistics
Market CapUS$634.26m
Earnings (TTM)-US$431.14m
Revenue (TTM)US$5.14m

123.4x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLUE income statement (TTM)
RevenueUS$5.14m
Cost of RevenueUS$283.98m
Gross Profit-US$278.84m
Other ExpensesUS$152.30m
Earnings-US$431.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.20
Gross Margin-5,424.92%
Net Profit Margin-8,387.88%
Debt/Equity Ratio0%

How did BLUE perform over the long term?

See historical performance and comparison